MyPractice | Updates
Electronic Health Record Communications

Questions? Contact your physician specialist / COA or Help Desk:

Akron General	330.344.6604 or Ag-helpdesk@ccf.org
Akron PPG	330.344.EPIC (3742)
Florida Weston	954.659.5555, option 1
Indian River	772.567.4311, ext. 3375
Main Campus / all other areas	216.444.HELP (4357)

Effective May 25, 2021 **Main Campus Inpatient Providers**

Order J&J COVID-19 vaccine for inpatient administration

Providers with prescribing rights can order the Johnson & Johnson (Janssen), one-shot COVID-19 vaccine for inpatients 18 years and older at main campus.

The **COVID-19 vaccine .5ml (PF) (JANSSEN) [174824]** order will be available as of May 25 on main campus preference lists. This order must be placed by a licensed independent practitioner (LIP), it cannot be ordered by a nurse.

The order frequency will default to once at 5pm to align with vaccine storage and administration workflows.



Clinical criteria for inpatient vaccination and provider talking points

- Considerations for vaccine deferral per the Advisory Committee on Immunization Practices and Centers for Disease Control and Prevention recommendations and clinical experts

Absolute Contraindications
- Acute infection with COVID-19 - Treatment of COVID-19 infection with convalescent plasma or COVID-19 directed monoclonal antibodies within the past 90 days   • Examples: bamlanivimab, etesevimab, casirivimab, imdevimab
Precautions: consider deferring vaccination or vaccinate on case-by-case basis
- Surgical procedure anticipated within the next 72 hours - Solid organ or bone marrow transplantation, CAR-T cell therapy: delay vaccination for 3 months - Admission for chemotherapy treatment - Receipt of rituximab or treatment for acute rejection within past 6 months - Acute illness including sepsis or septic shock

- The Johnson & Johnson (Janssen) vaccine is the third vaccine to get authorized for emergency use in the US and only requires one dose.
- It is authorized for emergency use by the FDA, for individuals age **18** and over.
- In the phase 3 clinical trial, the vaccine was shown to be **66%** effective in preventing moderate and severe COVID-19 disease 28 days after vaccination. Overall, the vaccine was also **85%** effective in preventing hospitalization and **100%** effective in preventing death, 28 days after vaccination.
- **Women aged < 50 years** can receive any FDA-authorized COVID-19 vaccine. However, they should be aware of the rare risk of thrombosis with thrombocytopenia syndrome (TTS) after receipt of the J&J vaccine and the availability of other FDA-authorized COVID-19 vaccines (i.e., mRNA vaccines). The highest rates of TTS per vaccine doses administered were identified in women <50 years of age. At the time of ACIP's review, TTS reporting rates to VAERS were 7.0 cases per million Janssen COVID-19 vaccine doses administered to women ages 18−49 years and 0.9 per million to women aged ≥50 years.
- Use was paused to review a small number of clotting events with low platelet counts in the U.S.
- The FDA recommended resuming the use of the vaccine as the events were deemed extremely rare, happening to a small percentage of people out of the 8 million who received the vaccine at the time of the pause.
- All of the cases occurred in women between the ages of 18 and 59 and symptoms occurred six to 15 days after vaccination.
- Patients and can monitor for headaches, stomach pain, leg pain or shortness of breath two to three weeks after getting the vaccine. Patients should contact a healthcare provider immediately if experiencing these symptoms in the two to three weeks following vaccination.
- The CDC has issued guidance on public health recommendations for those who are fully vaccinated from COVID-19. Individuals are considered fully vaccinated two weeks after receiving the Johnson & Johnson vaccine.